文献速递消化系统肿瘤

免疫联合治疗在MSS/pMMR型结直肠癌中的应用:现状与未来展望

[Application of immune combination therapy in MSS/pMMR-type colorectal cancer: current status and future perspectives].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2024-01-01

本文聚焦微卫星稳定(MSS)/错配修复完整(pMMR)型转移性结直肠癌(CRC)这一ICIs单药难以获益的人群,介绍免疫联合治疗的常见模式与可能机制,总结相关探索与进展及疗效预测标志物,并展望ICIs在该人群中的应用前景。

要点

  • ICIs仅对占少数的微卫星高度不稳定/错配修复缺失型转移性CRC疗效显著。
  • 占大多数的MSS/pMMR型转移性CRC几乎不能从ICIs单药治疗中获益。
  • 免疫联合治疗成为破解MSS/pMMR型CRC治疗难题的关键,本文总结其模式、机制与进展。

核心结论

  • MSS/pMMR型转移性CRC几乎不能从ICIs单药治疗中获益,免疫联合治疗成为破解这一临床难题的关键。

研究设计与样本

  • 本文为综述,介绍MSS/pMMR型CRC免疫联合治疗的常见模式和可能机制,总结相关探索与进展及疗效预测标志物,并展望应用前景。

主要发现

  • ICIs在恶性实体肿瘤中应用广泛且疗效显著,但在CRC中仅对占少数的微卫星高度不稳定/错配修复缺失型转移性CRC表现出显著治疗效果。
  • 占大多数的MSS/pMMR型转移性CRC几乎不能从ICIs单药治疗中获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In recent years, immune checkpoint inhibitors (ICIs) have been widely used in malignant solid tumors with remarkable efficacy. However, in colorectal cancer (CRC), ICIs have shown significant therapeutic effects only in patients with highly microsatellite unstable/mismatch repair-deficient metastatic CRC and these patients are only a minority of all CRC patients. In contrast, the majority of patients, those with microsatellite stable (MSS)/mismatch repair-complete (pMMR)-type metastatic CRC, could hardly benefit from ICI monotherapies, and immune combination therapies have become the key to solveing this clinical challenge. This article introduces the common patterns and possible mechanisms of immune-combination therapies for MSS/pMMR-type CRC, the exploration and progress made in the application of immune-combination therapies, as well as the possible predictive markers of efficacy of immune therapies. The prospects and directions of ICIs in the treatment of MSS/pMMR-type CRC are also discussed. 近年来,免疫检查点抑制剂(ICIs)在恶性实体肿瘤中应用广泛且疗效显著。然而,在结直肠癌(CRC)中,ICIs仅对占少数的微卫星高度不稳定/错配修复缺失型转移性CRC表现出显著的治疗效果,而占大多数的微卫星稳定(MSS)/错配修复完整(pMMR)型转移性CRC几乎不能从ICIs单药治疗中获益,免疫联合治疗成为破解这一临床难题的关键。文章介绍了MSS/pMMR型CRC免疫联合治疗的常见模式和可能机制,总结归纳了MSS/pMMR型CRC免疫联合治疗方面所做的探索和取得的进展以及免疫治疗疗效的可能预测标志物,对ICIs在MSS/pMMR型CRC治疗中的应用前景进行了展望。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang XL, Fan WX, Du YY, et al. [Application of immune combination therapy in MSS/pMMR-type colorectal cancer: current status and future perspectives]. Zhonghua Zhong Liu Za Zhi. 2024. PMID: 39143795. doi:10.3760/cma.j.cn112152-20230904-00116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。